Download PDF
Horm Metab Res 2003; 35(9): 511-516
DOI: 10.1055/s-2003-42650
Original Basic
© Georg Thieme Verlag Stuttgart · New York

Involvement of 5-HT2 Receptor in Imipramine-Induced Hyperglycemia in Mice

Y.  Sugimoto1 , K.  Inoue1 , J.  Yamada1
  • 1Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe, Japan
Further Information

Publication History

Received 30 December 2002

Accepted after Revision 14 April 2003

Publication Date:
30 September 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Effects of imipramine on plasma glucose levels were investigated in mice. Imipramine i. p. induced dose-dependent hyperglycemia, which was enhanced by pretreatment with 5-HT1/2/5/7 receptor antagonist methysergide and 5-HT2A/2B/2C receptor antagonist LY 53 857. 5-HT2C/2B receptor antagonist SB 206 553 also augmented imipramine-induced hyperglycemia although 5-HT1A and 5-HT1B receptor antagonist (-)-propranolol,5-HT2A receptor antagonist ketanserin and 5-HT3/4 receptor antagonist tropisetron each had no effect. Imipramine i. p.-induced hyperglycemia was antagonized by the 5-HT2C/2B receptor agonist 1-(3-chlorophenyl)piperazine (mCPP), while the 5-HT2B receptor agonist BW 723C86 had no effect. Intracerebroventricular injection of imipramine also elevated plasma glucose levels, which is enhanced by SB 206 553. Hyperglycemia elicited by central injection of imipramine was abolished by adrenalectomy. These results suggest that imipramine-induced hyperglycemia in mice is related to its inhibition of the central 5-HT2C receptor. Moreover, our results indicate that adrenaline release is related to imipramine-induced hyperglycemia.

Key words

Imipramine - 5-HT (5-hydroxytryptamine, serotonin) - 5-HT2C/2B Receptor - Glucose - Antidepressants

References

  • 1 Chaouloff F, Jeanrenaud B. 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.  J Pharmacol Exp Ther. 1987;  243 1159-1166
    PubMedGoogle Scholar
  • 2 Bouhelal R, Loubatieres-Mariani M M, Mir A K. Investigation of the mechanism(s) of 8-OH-DPAT-mediated inhibition of plasma insulin in spontaneously hypertensive rats.  Br J Pharmacol. 1990;  100 173-179
    PubMedGoogle Scholar
  • 3 Durcan M J, Wozniak K M, Linnoila M. Modulation of the hypothermic and hyperglycaemic effects of 8-OH-DPAT by a-α2-adrenoceptor antagonists.  Br J Pharmacol. 1991;  102 222-226
    PubMedGoogle Scholar
  • 4 Critchley D V, Middlefell V C, Liddle C W, Foden N D, Dourish C T. Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycemia in conscious rats.  Eur J Pharmacol. 1994;  254 133-139
    CrossrefPubMedGoogle Scholar
  • 5 Chaouloff F, Baudrie V, Laude D. Evidence that the 5-HT1A receptor agonists buspirone and ipsapirone activate adrenaline release in the conscious rat.  Eur J Pharmacol. 1990;  177 107-110
    CrossrefPubMedGoogle Scholar
  • 6 Sugimoto Y, Yamada J, Kimura I, Watanabe Y, Horisaka K. The Effects of the serotonin1A receptor agonist buspirone on the blood glucose and pancreatic hormones in rats.  Jpn J Pharmacol. 1992;  60 145-148
    PubMedGoogle Scholar
  • 7 Baudrie V, Chaouloff F. Mechanisms involved in the hyperglycemic effect of the 5-HT1C/5-HT2 receptor agonist DOI.  Eur J Pharmacol. 1992;  213 41-46
    CrossrefPubMedGoogle Scholar
  • 8 Sugimoto Y, Yamada J, Yoshikawa T, Horisaka K. Effects of the 5-HT2C/2B receptor agonist 1-(3-chlorophenyl)piperazine on the plasma glucose levels of rats.  Eur J Pharmacol. 1996;  307 75-80
    CrossrefPubMedGoogle Scholar
  • 9 Montgomery S A. Clinical efficacy of 5-HT uptake inhibitors.  Neuropharmacology. 1990;  13 285-286
    PubMedGoogle Scholar
  • 10 Hyttel J. Pharmacological characterization of the selective serotonin reuptake inhibitors(SSRI's).  Int J Pharmacol. 1994;  9 19-26
    PubMedGoogle Scholar
  • 11 Sugimoto Y, Inoue K, Yamada J. Involvement of serotonin in zimelidine-induced hyperglycemia in mice.  Biol Pharm Bull. 1999;  22 1240-1241
    PubMedGoogle Scholar
  • 12 Yamada J, Sugimoto Y, Inoue K. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms.  Eur J Pharmacol. 1999;  382 211-215
    CrossrefPubMedGoogle Scholar
  • 13 Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies.  J Clin Neuropharmacol. 1993;  16 24-35
    PubMedGoogle Scholar
  • 14 Kaplan S M, Mass J W, Pixley J M, Ross W D. Use of imipramine in diabetes.  J Am Med Assooc. 1960;  174 511-517
    PubMedGoogle Scholar
  • 15 Gupta B, Awasthi A, Jaju B P. Effect of acute & chronic imipramine treatment on glucose homeostasis.  Indian J Med Res. 1992;  96 65-71
    PubMedGoogle Scholar
  • 16 Haley T J, McCormick W G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.  J Pharmacol. 1957;  12 12-15
    PubMedGoogle Scholar
  • 17 Katz L M, Fochtman L F, Pato M T. Clomipramine, fluoxetine and glucose control.  Ann Clin Psychiatry. 1991;  3 271-274
    PubMedGoogle Scholar
  • 18 Palvimaki E P, Roth B L, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor.  Psychopharmacology. 1996;  126 234-240
    PubMedGoogle Scholar
  • 19 Borsini F, Cesana R, Vidi A, Mennini T. Evidence that imipramine activates 5-HT1C receptor function.  Eur J Pharmacol. 1991;  203 359-363
    CrossrefPubMedGoogle Scholar
  • 20 Redrobe J P, Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.  Eur J Pharmacol. 1997;  325 129-135
    CrossrefPubMedGoogle Scholar
  • 21 Yamada J, Sugimoto Y. Effects of 5-HT2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice.  Eur J Pharmacol. 2001;  427 221-225
    CrossrefPubMedGoogle Scholar
  • 22 Baxter G, Kennett G A, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united?.  Trends Pharmacol Sci. 1995;  16 105-110
    CrossrefPubMedGoogle Scholar
  • 23 Groenink L, van der Gugten J, Verdouw P M, Maes R A, Olivier B. The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects.  Eur J Pharmacol. 1995;  280 185-193
    CrossrefPubMedGoogle Scholar
  • 24 Groenink L, van der Gugten J, Zethof T J, van der Heyden J A, Olivier B. Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia test in mice.  Pharmacol Biochem Behav. 1996;  54 249-254
    CrossrefPubMedGoogle Scholar
  • 25 Bouhelal R, Mir A K. Role of the adrenal medulla in the metabolic and pressor actions of 8-OH-DPAT.  Br J Pharmacol. 1992;  105 159-163
    PubMedGoogle Scholar
  • 26 Chaouloff F, Laude D, Baudrie V. Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT.  Eur J Pharmacol. 1990;  185 11-18
    CrossrefPubMedGoogle Scholar
  • 27 Gaut Z N. Influence of various substances which induce and inhibit aggregation on the uptake of deoxyglucose by human blood platelets.  J Pharmacol Exp Ther. 1974;  190 180-186
    PubMedGoogle Scholar
  • 28 Pinkofsky H B, Dwyer D S, Bradley R J. The inhibition of GLUT1 glucose transport and cytochalasin B binding activity by tricyclic antidepressants.  Life Sci. 2000;  66 271-278
    PubMedGoogle Scholar

Y. Sugimoto

Department of Pharmacology · Kobe Pharmaceutical University

Motoyamakita-machi · Higashinada-ku · Kobe 658-8558 · Japan

Phone: +81(78)441-7573

Fax: +81(78)441-7574 ·

Email: yumisugi@kobepharma-u.ac.jp

      >